Assembly Biosciences Total Current Liabilities 2010-2024 | ASMB

Assembly Biosciences total current liabilities from 2010 to 2024. Total current liabilities can be defined as the sum of all liabilities classified as current for having maturities of less than one year.
Assembly Biosciences Annual Total Current Liabilities
(Millions of US $)
2023 $39
2022 $16
2021 $16
2020 $24
2019 $24
2018 $18
2017 $13
2016 $7
2015 $3
2014 $1
2013 $3
2012 $3
2011 $3
2010 $2
2009 $12
Assembly Biosciences Quarterly Total Current Liabilities
(Millions of US $)
2024-06-30 $41
2024-03-31 $39
2023-12-31 $39
2023-09-30 $7
2023-06-30 $9
2023-03-31 $10
2022-12-31 $16
2022-09-30 $15
2022-06-30 $15
2022-03-31 $11
2021-12-31 $16
2021-09-30 $15
2021-06-30 $14
2021-03-31 $14
2020-12-31 $24
2020-09-30 $17
2020-06-30 $17
2020-03-31 $21
2019-12-31 $24
2019-09-30 $21
2019-06-30 $20
2019-03-31 $25
2018-12-31 $18
2018-09-30 $15
2018-06-30 $13
2018-03-31 $12
2017-12-31 $13
2017-09-30 $12
2017-06-30 $12
2017-03-31 $11
2016-12-31 $7
2016-09-30 $7
2016-06-30 $5
2016-03-31 $4
2015-12-31 $3
2015-09-30 $3
2015-06-30 $2
2015-03-31 $2
2014-12-31 $1
2014-09-30 $1
2014-06-30 $1
2014-03-31 $1
2013-12-31 $3
2013-09-30 $2
2013-06-30 $3
2013-03-31 $2
2012-12-31 $3
2012-09-30 $3
2012-06-30 $3
2012-03-31 $4
2011-12-31 $3
2011-09-30 $1
2011-06-30 $1
2011-03-31 $0
2010-12-31 $2
2010-09-30
2010-06-30
2010-03-31
2009-12-31 $12
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.104B $0.007B
Assembly Biosciences, Inc. is a biopharmaceutical company. It develops therapies for infectious diseases and other disorders of the gastrointestinal (GI) system. Assembly's product portfolio consists of two late stage assets: VEN 307 for relief from pain associated with anal fissures and VEN 308 for the treatment of fecal incontinence. The Company is also developing novel microbiome-based technology for targeted oral delivery of therapeutic bacteria, complex proteins, viral antigens and small molecules to treat intractable infectious diseases of the GI tract, such as C. difficile infections. Assembly Biosciences Inc., formerly known as Ventrus Biosciences, Inc., is based in New York.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.679B 6.46
Dr Reddy's Laboratories (RDY) India $12.521B 23.96
BridgeBio Pharma (BBIO) United States $4.911B 0.00
Bausch Health Cos (BHC) Canada $3.439B 2.49
Amphastar Pharmaceuticals (AMPH) United States $2.335B 14.04
Supernus Pharmaceuticals (SUPN) United States $2.022B 27.53
Taysha Gene Therapies (TSHA) United States $0.334B 54.33
Personalis (PSNL) United States $0.261B 0.00
Sol-Gel Technologies (SLGL) Israel $0.015B 0.00
Evoke Pharma (EVOK) United States $0.004B 0.00
Teligent (TLGT) United States $0.000B 0.00